Acronym:
TreeTopp
ACTRN/NCT /ethics:
NCT03093870
Scientific title:
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer (TreeTopp)
Summary of trial and patient characteristics
| Cancer Type | Gall Bladder | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase III, Phase II | Tumour Stream | Biliary tract cancer |
| Age Range | All ages | Cancer Stage | Metastatic or Widespread, Locally Recurrent or Locally Advanced |
| Sex | Both | Anticipated Start Date | 2017-07-04 |
| Molecular Target | Anticipated End Date | 2019-07-01 | |
| Cancer Type | Gall Bladder |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III, Phase II |
| Age Range | All ages |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Biliary tract cancer |
| Cancer Stage | Metastatic or Widespread, Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2017-07-04 |
| Anticipated End Date | 2019-07-01 |
Trial Summary
This protocol for Varlitinib is developed for the treatment of Biliary Tract Cancer. Varlitinib (also known as ASLAN001) is a small-molecule, adenosine triphosphate competitive inhibitor of the tyrosine kinases - epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER)2, and HER4. Varlitinib may be beneficial to subjects with cancer by simultaneous inhibition of these receptors. The purpose of this study is to determine the safety and efficacy of Varlitinib in combination with capecitabine for the treatment of Biliary Tract Cancer. Treatment groups are Varlitinib+capecitabine and Placebo + capecitabine.
Lay Summary
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer (TreeTopp)
Sponsor / Cooperative group
Aslan Pharmaceuticals
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Professor Chris Karapetis | Completed |